Ignite Creation Date:
2024-05-05 @ 6:34 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00500227
Status:
COMPLETED
Last Update Posted:
2019-01-14
First Post:
2007-07-11
Brief Title:
Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery
Sponsor:
Ipsen
Organization:
Ipsen
Study Overview
Official Title:
Observational Study to Evaluate in Acromegalic Patients With Disease Persistence After Surgery Those Histopathologic Clinical Morphologic and Biochemical Factors Predictors of Hormonal Control Under Somatostatin Analogue Treatment
Status:
COMPLETED
Status Verified Date:
2019-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ESPORA
Brief Summary:
The objective of this study is to evaluate in acromegalic patients with disease persistence after surgery who are treated with somatostatin analogues the histopathological clinical morphological and biochemical factors which are predictive of hormonal control
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None